Is Kopran a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Kopran Ltd is a average quality company .

Is Kopran undervalued or overvalued?

The key valuation ratios of Kopran Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Kopran share price return in the past 10 years?

Kopran Ltd share price has appreciated 17% annually (CAGR) over the past ten years.

Is Kopran a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Kopran Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

Kopran Ltd - Stock Valuation and Financial Performance

Name: Kopran
Brand: Kopran

BSE: 524280 | NSE: KOPRAN | Pharmaceuticals & Drugs | Small Cap

Place order

Kopran Share Price

₹324.75 0.50 0.15%
as on 20-Sep'24 16:01

10 Year X-Ray of Kopran:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	11.4%	9.5%	9.5%	5.3%	8.7%	8%	13.6%	5.6%	9.4%	11.4%	-
Value Creation Index ⓘ	-0.2	-0.3	-0.3	-0.6	-0.4	-0.4	0.0	-0.6	-0.3	-0.2	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	326	187	182	154	197	179	223	205	273	337	321
Sales YoY Gr.	-	-42.5%	-3.1%	-15.3%	27.9%	-8.8%	24.3%	-8.2%	33.5%	23.6%	-
Adj EPS ⓘ	1.6	2.8	0.6	0	3.1	2.6	4.1	1.8	6.4	6.6	8
YoY Gr.	-	80%	-77.8%	-96.8%	15250%	-14%	54.2%	-54.8%	249.5%	1.9%	-
BVPS (₹) ⓘ	39.6	43.5	46.5	47.6	50.5	53.1	57.1	78.6	82.1	86.3	87.1
Adj Net Profit ⓘ	6.4	12.1	2.7	0.1	13.3	11.4	17.6	8.9	31	31.6	39
Cash Flow from Ops. ⓘ	52.6	18.7	4.2	12.5	11.8	10	48.8	-37.8	16.9	35	-
Debt/CF from Ops. ⓘ	0.7	1.8	13.4	4.2	4.2	4.6	0.3	-1	1.7	0.7	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	0.4%	11.4%	14.8%	23.6%
Adj EPS ⓘ	17.4%	16.4%	17.2%	1.9%
BVPSⓘ	9%	11.3%	14.8%	5.1%
Share Price	17%	60.4%	14.7%	46%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	3.9	6.3	1.4	0	6.3	5.1	7.4	2.8	8	7.8	9.3
Op. Profit Mgn % ⓘ	9.7	13.3	9.6	4.7	11.8	13.1	13.5	7.5	10.4	10.9	12.9
Net Profit Mgn % ⓘ	2	6.4	1.5	0.1	6.8	6.4	7.9	4.3	11.4	9.4	12.1
Debt to Equity ⓘ	0.2	0.2	0.3	0.3	0.2	0.2	0.1	0.1	0.1	0.1	-
Working Cap Days ⓘ	221	267	188	233	186	229	187	236	231	204	95
Cash Conv. Cycle ⓘ	36	2	25	48	42	84	55	87	83	73	44

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 9.30%

Sales growth is growing at healthy rate in last 3 years 14.84%

Net Profit is growing at healthy rate in last 3 years 17.19%

Sales growth is good in last 4 quarters at 23.35%

No data to display

Latest Financials - Kopran Ltd.

	Standalone	Consolidated
TTM EPS (₹)	8	12.3
TTM Sales (₹ Cr.)	321	637
BVPS (₹.) ⓘ	87.1	104
Reserves (₹ Cr.) ⓘ	372	453
P/BV ⓘ	3.70	3.10
PE ⓘ	40.11	26.20

From the Market
52 Week Low / High (₹)	185.65 / 369.20
All Time Low / High (₹)	6.40 / 558.84
Market Cap (₹ Cr.)	1,553
Equity (₹ Cr.)	48.2
Face Value (₹)	10
Industry PE ⓘ	47.6

Management X-Ray of Kopran:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Kopran

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Kopran

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	326	187	182	154	197	179	223	205	273	337
Operating Expenses ⓘ	294	162	164	146	174	156	193	189	245	301
Manufacturing Costs	43	22	26	28	30	29	31	37	39	45
Material Costs	194	103	95	77	102	86	121	107	156	205
Employee Cost	29	16	19	18	20	20	18	21	25	26
Other Costs ⓘ	28	22	24	23	21	21	23	25	25	25
Operating Profit ⓘ	32	25	17	7	23	23	30	15	28	37
Operating Profit Margin (%)	9.7%	13.3%	9.6%	4.7%	11.5%	12.9%	13.5%	7.5%	10.2%	10.9%
Other Income ⓘ	6	1	9	10	3	2	10	8	16	17
Interest ⓘ	13	10	10	7	5	6	4	3	3	5
Depreciation ⓘ	10	3	3	3	3	3	4	4	4	5
Exceptional Items ⓘ	0	-1	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	15	11	13	7	17	16	33	16	37	45
Tax ⓘ	0	0	5	2	4	5	9	4	6	10
Profit After Tax	15	11	9	5	13	11	23	12	31	35
PAT Margin (%)	4.8%	6.1%	4.7%	3.1%	6.6%	6.3%	10.5%	5.7%	11.4%	10.3%
Adjusted EPS (₹)	3.8	2.6	2.0	1.1	3.0	2.6	5.4	2.4	6.5	7.2
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	28%	123%	46%	42%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	171	197	201	206	218	230	247	379	396	416
Share Capital ⓘ	50	52	43	43	43	43	43	48	48	48
Reserves ⓘ	122	145	158	162	175	186	204	331	347	368
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	26	29	50	45	41	36	16	37	28	23
Long Term Debt	8	22	28	22	22	10	2	2	2	2
Short Term Debt	18	7	22	24	19	27	13	35	26	20
Trade Payables	36	36	36	29	32	32	40	30	62	52
Others Liabilities ⓘ	41	18	19	17	24	28	22	19	20	21
Total Liabilities ⓘ	275	279	306	297	316	326	324	464	506	511
Fixed Assets
Gross Block	78	83	43	45	51	56	65	68	73	82
Accumulated Depreciation	45	48	3	7	10	13	17	21	26	30
Net Fixed Assetsⓘ	33	35	39	38	42	43	47	46	47	52
CWIP ⓘ	0	0	4	8	7	7	3	3	4	5
Investmentsⓘ	46	156	157	157	158	158	159	259	260	261
Inventories	14	28	25	30	25	41	28	42	48	49
Trade Receivables	29	20	38	20	45	42	49	59	84	88
Cash Equivalents	4	4	2	2	1	1	3	3	3	7
Others Assetsⓘ	148	35	40	42	39	33	35	52	61	48
Total Assets ⓘ	275	279	306	297	316	326	324	464	506	511

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	53	19	4	12	12	10	49	-38	17	35
PBT ⓘ	15	11	13	7	17	16	33	16	37	45
Adjustment ⓘ	22	13	16	6	3	12	7	4	-9	3
Changes in Working Capital ⓘ	15	-6	-24	3	-5	-14	14	-55	-5	-2
Tax Paid ⓘ	0	0	-1	-3	-4	-4	-5	-4	-6	-10
Cash Flow From Investing Activity ⓘ	-10	-4	-9	-2	-4	1	-9	-100	10	-6
Capex	-11	-5	-12	-5	-6	-5	-4	-3	-6	-10
Net Investments	1	-1	0	0	0	0	-2	0	0	0
Others ⓘ	1	3	3	4	1	5	-2	-97	16	4
Cash Flow From Financing Activityⓘ	-43	-15	5	-11	-7	-11	-40	138	-26	-24
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	126	0	0
Net Proceeds from Borrowing ⓘ	0	0	-14	0	0	0	-9	0	0	0
Interest Paid ⓘ	-13	-10	-10	-7	-5	-6	-4	-3	-3	-5
Dividend Paid ⓘ	0	0	0	0	0	0	-6	-6	-14	-14
Others ⓘ	-30	-5	28	-4	-2	-5	-20	21	-9	-5
Net Cash Flow ⓘ	0	0	0	0	0	0	0	0	1	5

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	10.34	6.52	4.37	2.31	6.12	5.01	9.85	3.75	8.07	8.54
ROCE (%)	11.44	9.45	9.5	5.28	8.67	7.98	13.57	5.64	9.44	11.36
Asset Turnover Ratio	1.11	0.68	0.62	0.51	0.64	0.56	0.69	0.52	0.56	0.66
PAT to CFO Conversion(x)	3.53	1.73	0.44	2.4	0.92	0.91	2.13	-3.17	0.55	1
Working Capital Days
Receivable Days	46	47	58	69	60	89	75	97	96	93
Inventory Days	37	41	53	65	51	68	56	62	60	53
Payable Days	68	128	137	154	109	134	106	119	107	102

Kopran Ltd Stock News

Kopran Ltd FAQs

What is the share price of Kopran?

Company share prices are keep on changing according to the market conditions. The closing price of Kopran on 20-Sep-2024 16:01 is ₹324.8.

What is the market cap of Kopran?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Sep-2024 16:01 the market cap of Kopran stood at ₹1,553.4.

What is the P/E ratio of Kopran?

The latest P/E ratio of Kopran as of 20-Sep-2024 16:01 is 40.11.

What is the P/B ratio of Kopran?

The latest P/B ratio of Kopran as of 20-Sep-2024 16:01 is 3.70.

What is the 52-week high and low of Kopran?

The 52-week high of Kopran is ₹369.2 and the 52-week low is ₹185.7.

What is the TTM revenue of Kopran?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kopran is ₹321.2 ( Cr.) .

About Kopran Ltd

The company was incorporated on April 26, 1958 as a private limited company under the name Kopran Chemical Company Pvt. Ltd. by Ramanlal V Shah Sevantilal, A Shah , Chimanlal G Sheth and Jivanalal M Shah. In 1972, the companyâ€™s management was acquired by Chemo Pharma Laboratories Ltd and the Companyâ€™s products were marketed by them.

Promoted by the Parijat Enterprises, Kopran is currently an integrated health care company. Kopran has used research-based technology to contribute towards total health-care. The company started modestly as a Semi Synthetic Penicillin (SSP) player and expanded to becomes the largest SSP Player in India with an annual SSP facility of over 1200 tones per annum.Subsequently the SSP business was hived off into a separate Company in a joint venture with Synpac Pharmaceuticals Ltd, UK.Kopran Laboratories Ltd. markets and supports high-tech life-saving medical equipments and diagnostics reagents since 1988.

Kopran Research Laboratories Ltd. (KRLL) is an emerging research organisation with particular interests in the areas of drug discovery, polymer technology and synthesis of new molecules.

Kopran is working towards creating and maintaining a global presence.Presence in Africa through Kampala Pharmaceutical Industries (KPI),a pharmaceutical company engaged in the manufacture and marketing of finished dosage forms in Uganda.

The company is having presence in the Middle East Market through a joint venture with Dubai Investment Corporation a leading investment company in Dubai for the manufacture and marketing of finished dosage forms in Dubai.

KRLL is a 100% subsidiary of Kopran Ltd. KRLL is recognised by the Department of Science and Industrial Research (DSIR), Government of India. The company is staffed with competent and dedicated team of scientists.

Product range of the company includes:

Finished Dosage Forms

Antibiotics/antibacterials
Anti-malarial
Cadiovasculars
Pain management
Anthelminthics
Antiprotozoals
Antidiabetics
Gastrointestinals
Drug for erectile dysfuntion
Antiallergics
Respiratory/anti-asthmatics
Metered dose inhalers
Dry powder inhalers
Antiviral

Active Pharmaceutical Ingredients

Anti-hypertensives
Macrolides
Taste Masked
Cephalosporins
Under Development
Others

Achievements/ recognition:

Kopran has a state of art manufacturing plants (Penicillin & General) approved by: -MCC (South Africa) -TGA, Australia and FDA, USA are in the pipeline

Future plans: